Detail akcie Galmed Pharmaceutic online

Business Summary: Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Galmed Pharmaceuticals Ltd revenues was not reported. Net loss increased 27% to $5.5M. Higher net loss reflects Research and development expenses increase of 46% to $2.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$7.24 to -$1.60.